Search

Displaying results 5781 - 5790 of 10000 in total
  1. Drug

    AMT-080

    go.drugbank.com/drugs/DB17846
    Experimental

    AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.

  2. Drug

    CTX130

    go.drugbank.com/drugs/DB18627
    Investigational

    CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.

  3. Drug

    AG-24322

    go.drugbank.com/drugs/DB13035
    Investigational

    AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.

  4. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.

  5. Drug

    Apolizumab

    go.drugbank.com/drugs/DB06467
    Investigational

    Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

  6. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

  7. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  8. Drug

    4-Phenylfentanyl

    go.drugbank.com/drugs/DB09168
    ExperimentalIllicit

    4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted … thiophenes and thiazoles are more potent still, as they are closer bioisosteres to the 4-carbomethoxy group of carfentanil.

  9. Drug

    BD-111

    go.drugbank.com/drugs/DB18247
    Investigational

    BD-111 is an HSV-1-erasing lentivirus-like particle delivering gRNA-expressing cassette and SpCas9 mRNA.

  10. Drug

    HSV-2 theracine

    go.drugbank.com/drugs/DB05811
    Experimental

    HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.